Incidence, Prevalence, and Stability of Remission in Individuals With Clinical High Risk for Psychosis

作者：Johanna Seitz‐Holland, Grace R. Jacobs, Jenna Reinen, Daniel H. Mathalon, Cheryl M. Corcoran, Abraham Reichenberg, Márk Vangel, Robert J. Glynn, Nora Penzel, Kang-Ik K. Cho, Eduardo Castro, Anastasia Haidar, Jean Addington, Tina Kapur, Sylvain Bouix, Carrie E. Bearden, John M. Kane, Patrick D. McGorry, Scott W. Woods, Barnaby Nelson, René S. Kahn, Martha E. Shenton, Guillermo Cecchi, Ofer Pasternak · 发表于：JAMA Network Open · 年份：2025 · DOI：10.1001/jamanetworkopen.2025.25644 · 被引用次数：5 · 研究领域：Schizophrenia research and treatment、Mental Health and Psychiatry、Healthcare Decision-Making and Restraints

Importance: While remission from clinical high risk (CHR) for psychosis is a favorable outcome, it is not well characterized over time. Objective: To examine remission incidence, prevalence, and stability, and their association with demographic, clinical, medication, and cognitive variables, comparing 2 commonly used definitions. Design, Setting, and Participants: This cohort study examined data from individuals aged 12 to 30 years at CHR in the North American Prodromal Longitudinal Study 3, collected from 9 sites across the US from February 2015 to November 2018. Statistical analyses were conducted between January 2023 and May 2025. Exposure: CHR status using 2 definitions: (1) a symptoms-only definition based on the positive symptoms from the Scale of Prodromal Symptoms and (2) a symptoms-and-function definition based on positive symptoms and the modified Global Assessment of Functioning. Main Outcomes and Measures: The primary outcomes were remission incidence, prevalence, and stability for 7 follow-up visits over 2 years. Associations of remission with age, sex at birth, race, antipsychotic and antidepressant medication, history of trauma, and cognitive performance were determined using mixed-effects logistic regression. Results: The sample included 692 individuals (mean [SD] age, 18.7 [4.1] years; 319 female [46%]) at baseline, with 614 completing at least 1 follow-up. For the symptoms-only definition, 7% (95% CI, 5%-10%) met remission criteria after 2 months, 34% (95% C...